怡然一笑
Lv3
230 积分
2023-04-23 加入
-
103-OR: LX9211, an Orally-Administered, Non-opioid, AAK1 Inhibitor for Painful Diabetic Peripheral Neuropathy—Results from a Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study
1年前
已关闭
-
An overview of the safety and efficacy of LX-9211 in treating neuropathic pain conditions
1年前
已完结
-
Deuterated active pharmaceutical ingredients: A science‐based proposal for synthesis, analysis, and control. Part 1: Framing the problem
1年前
已关闭
-
Impact of ICH Q11 Questions and Answers on the Outcome of Active Pharmaceutical Ingredient Starting Material Proposal Acceptance by ICH Regulatory Members
1年前
已完结
-
Particle size specifications for solid oral dosage forms: A regulatory perspective
1年前
已关闭
-
Advances in steroid research from the pioneering neurosteroid concept to metabolomics: New insights into pregnenolone function
1年前
已完结
-
Signaling-specific inhibition of the CB1 receptor for cannabis use disorder: phase 1 and phase 2a randomized trials
1年前
已完结
-
A mild and selective Cu(II) salts-catalyzed reduction of nitro, azo, azoxy, N-aryl hydroxylamine, nitroso, acid halide, ester, and azide compounds using hydrogen surrogacy of sodium borohydride
1年前
已完结
-
Discovery of selective NaV1.8 inhibitors based on 5-chloro-2-(4,4-difluoroazepan-1-yl)-6-methyl nicotinamide scaffold for the treatment of pain
1年前
已完结
-
Selective Inhibition of NaV1.8 with VX-548 for Acute Pain
1年前
已完结